madman
Super Moderator
Most men who undergo a prostate biopsy may not have cancer found at all—and the bigger mistake may be rushing from a single elevated PSA straight to the needle.
Dr. James Wysock, an NYU urologist with deep expertise in prostate cancer diagnostics and image-guided biopsy, explains why the modern biopsy decision is no longer about PSA alone. Repeat testing, prostate MRI, PSA density, blood and urine biomarkers, and expert image targeting can dramatically change who should be biopsied and how that biopsy should be performed.
Just as surprising: transperineal biopsy is not automatically “better” in every case. It clearly lowers infection and antibiotic exposure, but biopsy accuracy still depends heavily on imaging, fusion quality, sampling technique, and operator experience.
In this episode, you’ll learn:
* Why one elevated PSA should often be repeated before escalating testing.
* Why MRI may be the most important next test when biopsy risk remains concerning.
* How transperineal and transrectal biopsies really compare.
* How new fusion, needle and tissue-preservation technologies could make future biopsies shorter, more precise and less invasive.
CHAPTERS
00:00 Biopsy Myth Busting
01:26 Meet Dr Wysock
03:01 Biomarkers Beyond PSA
12:27 Repeat PSA First
19:46 MRI Leads The Way
26:38 Micro Ultrasound Explained
29:09 Future Without Biopsy
31:44 Transperineal Vs Transrectal
42:10 Patient Experience And Pain
49:13 Next Gen Biopsy Tech
55:56 Wrap Up And Resources
